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Cardiac rehabilitation (CR) programs are effective in reducing cardiovascular mortality and 
readmissions. However, most patients are denied the benefits of CR due to low referral rates. 
Of those patients referred, commencement rates vary from 28.4% to 60%. This paper 
quantifies the scale of health loss in Australia due to poor engagement with the program, and 
estimates how much public funding can be justifiably reallocated to address the problem.  
Methods 
Economic decision modelling was undertaken to estimate the expected lifetime health loss 
and costs to Medicare. Key parameters were derived from Australian databases, CR registries 
and meta-analyses. Population health gains associated with uptake rates of 60%, and 85% 
were calculated. 
Results 
CR was associated with a 99.9% probability of being cost-effective, even at a cost-
effectiveness threshold lower than conventionally applied. Importantly, an average of 0.52 
years of life expectancy are lost due to national uptake being below 60% achieved in some 
best performing programs in Australia, equivalent to 0.28 quality adjusted life years.  
The analysis indicates that $12.9 million/year could be justifiably reallocated from public 
funds to achieve a national uptake rate of 60%, while maintaining cost-effectiveness of CR 











CR is a cost-effective service for patients with coronary heart disease. In Australia, less than 
a third of patients commence CR, potentially resulting in avoidable patient harm. Additional 
investment in CR is vital and should be a national priority as the health gains for patients far 
















Coronary heart disease (CHD) is the leading cause of death and morbidity in Australia [1]. 
One in five patients hospitalised with AMI will experience an unplanned readmission within 
30 days of discharge for any cause [2]. Cardiac rehabilitation (CR) programs are crucial in 
ensuring long term patient health and reducing readmissions in these patients. The efficacy 
associated with CR is well established, with a 26% reduction in CV mortality and 18% 
reduction in readmissions for patients participating in CR compared to no CR [3]. CR 
programs are now recommended as standard care post ST-elevated myocardial infarction 
(STEMI), percutaneous coronary intervention (PCI) and coronary artery bypass surgery 
(CABGS) in national and international guidelines [4-6]. However, despite these benefits and 
recommendations, referrals to a CR program and subsequent attendance remains low, with 
only a third of eligible patients referred to a CR program in Australia [7]. Of those patients 
referred, only 28% of patients attend CR [7], with a high proportion failing to complete [8]. 
From an Australian perspective, the lifetime economic costs and life years gained from CR 
are unknown, with no research confirming the cost-effectiveness of its current provision, with 
international evidence only recently starting to emerge [9,10]. 
 
Traditional CR programs in Australia comprise of face-to-face sessions with one hour of 
supervised exercise and one hour of education on pre-determined topics conforming to 
national standards [11-14]. A recent paper by Astley, Chew, Keech, Nicholls et al. analysed 
data of 49 909 patients admitted to hospitals in South Australia with a STEMI, PCI or 
CABGs between 2013-2015 [7]. Of these, 15 089 (30.2%) people were referred to CR post-
discharge, however, only 28.4% of those referred attended the first session [7]. Several 
strategies have been implemented to improve the rate of uptake of CR, unfortunately, to no 










mode of delivery, the rate of uptake remains low [8]. In seeking to increase uptake, it is 
important to consider the health benefits that could be achieved if uptake rates approach the 
international gold standard of 85%, and therefore the investment that could be justified in 
achieving increased uptake.  
 
Using Australian data to update an existing model of CR [15], this paper will: a) determine 
the cost-effectiveness of CR programs over a lifetime as they are currently delivered, to 
explore if the current provision represents a justifiably use of limited health care resources, b) 
determine the health care budget that can be justifiably reallocated to achieve current uptake 
targets whilst maintaining cost-effectiveness, c) explore how the costs and health outcomes 
(life years and quality adjusted life years, QALYs) accrue over time to understand how the 




A pragmatic search of the literature relating to cost-effectiveness of CR programs and for CR 
parameters used in the existing model, from an Australian context, was undertaken. Only a 
small number of studies were identified for use in this cost-effectiveness analysis. A 
comprehensive Cochrane review was also used to inform the analysis as it explored the 
impact of CR on four outcomes: recurrent MI, revascularisation with either a PCI or CABGs 
or mortality [3].  
 
Population 
There are an estimated 62 400 acute coronary events annually in Australia resulting in 










patients with CHD are referred to a CR program [11]. However, the proportion of patients 
nationally that are appropriate for referral is unknown due to a lack of national data. State-
specific data, however, indicates a referral rate to CR of 30% [7]. The modelled cohort started 
at the age of 65 and had a male to female ratio of 0.74 to be indicative of current national 
programme demographics [7].  
  
Intervention 
CR programs comprise of 8-12 weeks of supervised prescribed exercise, behaviour change 
interventions to improve cardiac risk factor profile and psychosocial wellbeing. Health 
education about their condition and associated comorbidities together with self-management 
are key components of an effective CR intervention. There is a large degree of heterogeneity 
between length of programs and models of delivery such as face-to-face, group sessions, 
home-based programs and web-based programs. Studies have shown there are no statistically 
significant differences in psychosocial and physical fitness outcomes in CR programs 
utilising supervised group-based programs compared to self-delivered programs (home-based 
or web-based programs) [16,17]. Despite this heterogeneity in program delivery, the core 
components of CR programs strive to comply with the national standards [11-14].  
 
Model structure 
In economic evaluation, decision analytical models are used to determine the cost-
effectiveness of an intervention [18], in this case CR. An existing Markov cohort model 
comprising of four states (death, revascularisation with PCI or CABG or recurrent MI) was 
adapted to explore the impact of CR on the health of patients and costs over a lifetime, from 
an Australian health system perspective (figure I [15]). Patients entered the model ‘well’ post 










attend. Subsequently, patients transition into one of three branches: die, stays out of hospital 
or admitted to hospital with recurrent MI with no revascularisation or revascularisation with 
PCI or CABG. Probabilities of patients transitioning between these states differs according to 
whether these patients attended CR or not. The transition probabilities that determine the rate 
that patients move between the states is primarily informed by an international Cochrane 
review [3]. In all of these branches, patients can die from cardiovascular disease (CVD), 




See Figure I (markov model structure) 
 
The cost-effectiveness analysis was conducted from an Australian health care perspective 
with a lifetime time horizon and a six-month cycle length. All costs and outcomes were 
discounted annually by 5%, as per Australian guidelines [19]. The incremental cost-
effectiveness ratio (ICER) was compared to an estimate of marginal productivity ($28 
033/QALY) as calculated by Edeny, Afzali, Cheng, & Karnon [20] for an Australian 
population as well as the conventionally applied cost-effectiveness threshold of $50 
000/QALY [21].  The threshold estimates the point at which an increase in uptake of CR is 
no longer considered cost-effective for the health system to fund on the grounds of the QALY 













To populate the model, evidence is drawn from a variety of different sources, including the 
Queensland CR registry [22], Australian population data [23] and an analysis of South 
Australian CR programs from an administrative dataset [7]. Parameters used to inform the 
base-case analysis are provided in Table 1 in the Supplementary Appendix. The results of the 
meta-analysis by Anderson et al. [3] provided many of the parameter estimates which were 
converted from risk ratios to transition probabilities. Other data sources used to estimate 
model parameters are listed in Table II in the Supplementary Appendix.  
 
 
Quality of life was applied as a state specific decrement to an age-adjusted healthy population 
of QoL scores [27].  
 
Costs 
The unit costs were sourced from the National Hospital Cost Data Collection from the 
Independent Hospital Pricing Authority (IHPA) [28]. The cost of CR was unavailable in 
Australia so the cost was sourced from the UK NHS, as used in the original Markov model 
[15], and then converted to Australian dollars (AUD) using purchasing power parity [29].  
 
The NACR report showed only 76% of patients completed a CR program [9]. There is a large 
degree of variability in timing of when a patient withdraws from the program. Australian data 
regarding the timing of withdrawal was not available so a fractional cost was unable to be 
applied. To ensure a conservative approach to costing, in the base case analysis, the cost of 
CR was applied to all patients regardless of whether they completed the full program, as 










conservative assumption we assumed that any patient who failed to complete the full program 
received no health benefits. 
 
Sensitivity analysis 
A probabilistic sensitivity analysis (PSA) was conducted to explore uncertainty in the input 
parameters [30]. This approach incorporated the uncertainty reported in the meta-analysis by 
Anderson et al. [3] about the effectiveness of CR. Distributions were applied to the 
parameters within the model (see Table II) and Monte Carlo simulation used to generate 3000 
iterations of costs and QALYs. The probability of CR being cost-effective was determined, 
along with the justifiable expenditure to increase the uptake of CR. 
 
Results 
CR was associated with an average of 8.58 life years (undiscounted) compared to 8.06 life 
years in people who did not participate in CR. This implies a life expectancy increase to 
73.58 years in those undertaking CR (from 73.06) in the base-case cohort. CR also had higher 
discounted costs and QALYs compared to no CR (Table I). CR was considered cost-effective 
with a mean ICER of $6096/QALY with 98.7% probability of being cost-effective with high 
certainty at a cost-effectiveness threshold of $28 033 [20]. At the conventional threshold of 
$50 000 [21], CR continued to be cost-effective with a mean ICER of $6000 and 99.9% 
probability of being cost-effective. Scatterplots of the probabilistic simulations for 
completion and non-completion of CR, based on a 28.4% uptake rate, are provided in the 
Supplementary Appendix (figure Ia and Ib).  
 
 












Effect of Increasing CR attendance 
 
Estimates of the lifetime health gains for those engaging in CR over one year (QALYs) and 
justifiable expenditure to reach a target attendance rate of 59.6% and 85% (assuming current 
completion rates) are shown in Table II. The uptake rate of 59.6% was taken from the 
Queensland Cardiac Outcomes registry (QCOR) [22] for CR and therefore represents an 
achievable Australian target, and 85% an international gold standard uptake rate for CR 
programs [31]. The lifetime health gain was calculated by combining the increment required 
to reach target, estimated annual eligible population and the QALY gained per person 
commencing CR (Table II).  
 
With a current national uptake rate of 28.4% [7], the average health gained for reaching the 
target of 59.6% [22] would be 0.28 QALY per person referred to CR. The justifiable cost is 
an estimate of the funding that can be reallocated from elsewhere in Medicare to achieve the 
uptake target given the relative cost-effectiveness of CR compared to the marginal 
productivity of the healthcare system. The estimated total justifiable expenditure for the 
whole population is $12,908,207/year if CR uptake was to increase to 59.6% (Table II). If the 
uptake rate is further increased to 85%, there is a greater total health gain of 794 QALY gain 
for reaching target at a justifiable cost for the whole population of $23,416,812/year.  
 











If a 59.6% uptake of CR was achieved, our analysis suggests this would result in a reduction 
of 823 hospital admissions and 536 deaths avoided over 10 years. When this is increased to 
85% uptake target, this would result in a reduction of 1,493 hospital admissions and 972 
deaths avoided.  
Trends in cumulative undiscounted costs and outcomes over the lifetime of the average 
patient are displayed in Figures II demonstrating how the short-term additional cost of CR 
compares to the longer-term cost and health outcomes.  Figure IIb shows an initial higher cost 
for CR, however, both groups (CR vs no CR) are followed by a period of similar cumulative 
costs, as the CR patients have less interventions due to better health. Over time, the two lines 
separate due to the CR patients living longer, and therefore experiencing more health care 
costs. For both the life years (Figure IIa) and QALYs (Figure IIc), the two groups are similar 
for the first five years after the event, as there are f w deaths in either arm, however beyond 
this the additional health gains from CR are realised and the two curves separate.  
Figure IId shows the combined impact of these changes in cumulative costs and health 
outcomes over time, with the initial high relative cost of CR resulting in an ICER beyond 
cost-effectiveness thresholds.  However, within five years the significant health gains of CR 
and similar costs between the two arms leads to an ICER well below the threshold. 
Insert figure II comparison of no CR to CR over a lifetime 
Discussion 
To our knowledge this is the first study to evaluate the lifetime cost-effectiveness of CR 
based on Australian data. CR was cost-effective with high certainty and a mean ICER of 
$6096/QALY, well below recent estimates of the marginal productivity of Medicare or the 
conventionally applied cost-effectiveness threshold. Patients participating in CR experience 










model suggests if the uptake of CR was increased to 59.6% then it could potentially reduce 
hospitalisation by 823 episodes and 536 fewer deaths over 10 years.  The justifiable 
expenditure also provides decision makers with an estimate of the funding that can be 
reallocated to invest in improving the uptake rate. This evaluation provides important 
economic data that can be used in a business case advocating for return on investment in CR 
programs and to justify further research on interventions to increase the uptake of CR [32]. 
De Gruyter, Ford & Stavreski, [33] conducted a cost benefit analysis of CR programs in 
Victoria, Australia. They found there was a net financial saving of $46.7-$86.7 million over 
10 years with an uptake of 30%, 50% and 65%. There are some distinctive differences 
between this study and De Gruyter et al.’s study [33]. Firstly, they conducted a cost-benefit 
analysis using a simple decision tree. The mortality rates used by De Gruyter et al. [33] were 
based on a single centre study conducted in 1998 rather than the results of a meta-analysis as 
in the current analysis. De Gruyter et al. [33] used a time horizon of 10 years compared to a 
lifetime time horizon in the current evaluation. Their decision tree comprised of two 
transition states of hospitalisation or no hospitalisation. In the current study, there were four 
transition states: dies, stays out of hospital or admitted to hospital with recurrent MI with no 
revascularisation or revascularisation with PCI or CABG. 
This evaluation has shown the health benefits and costs associated with improving the uptake 
of CR. In addition to improving the rate of uptake, it is equally important to ensure that 
completion rates are also high to ensure maximisation of health benefits. A recent meta-
analysis showed that an increase in interventions to promote adherence to CR programs also 
resulted in a 13% increase in completion rates [34]. An International Council and Canadian 
Association of Cardiovascular Prevention and Rehabilitation position statement made three 










level of evidence), particularly face-to-face (strong level of evidence) and part of the CR 
program could be delivered remotely (weak level of evidence) [32].  
 
Limitations 
There were several limitations associated with the economic evaluation. A lack of national 
Australian CR data was problematic, necessitating the use of data from international sources 
including meta-analysis [3] and the UK National Audit of Cardiac Rehabilitation (NACR) 
[9]. The cost of CR was taken from NACR and a previous cost-effectiveness analysis [15]. 
Purchasing power parity was used to convert this cost to Australian dollars [29]. The use of 
purchasing power parity is a more rigorous method of currency conversion than exchange 
rates as it excludes cost of living and profits from traded goods compared to a straight 
conversion of sterling pounds to Australian dollars, but cannot consider differences in the 
average CR programme delivered. National Australian data is vital in order to truly estimate 
population health gains, to facilitate an improved understanding of the utilisation and uptake 
of CR in Australia. 
The model structure potentially over simplifies outcomes associated with an acute coronary/ 
STEMI event as outcomes associated with stroke, heart failure, arrythmias, multimorbidity 
and long-term disability were not included. However, the meta-analysis that was used to 
inform the parameters (Table II) did not include these outcomes.  
 
Conclusion 
CR is a cost-effective strategy for patients’ post-discharge from an acute coronary event due 










rates of uptake. If CR uptake was increased to 60% our analysis estimates an additional 438 
QALYs would be gained for every annual cohort of CR patients, as estimated $12.9 million 
could be reallocated within Medicare to achieve this target. Additional investment in CR is a 
national priority particularly as the health gains for CHD patients far outweigh the costs. 
Improving outcomes in these patients can be achieved by additional investment in increasing 
the uptake of CR post-discharge.  
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Figure I: Schematic of economic model 
 
Figure II comparison of  no CR to CR over a lifetime  
 
Figure a: Number of life years comparing no CR to CR over a lifetime             Figure b: Comparison of 
undiscounted costs of no CR with CR over a lifetime 
 
Figure c: Comparison of QALYs over a lifetime                                                       Figure d: Changes in 











































QALY= Quality adjusted life years 



























QALY= Quality adjusted life years 









Health gain for 
reaching target, 
QALY per 





LY gains Justifiable expenditure to 
reach target while cost-
effective 
Per person Whole 
population 
Target rate of 59.6% 
28.4% 31.2% 5030 0.28 438 8.58 $8,225 $12,908,207 
Target rate of 85% 
28.4% 56.6% 5030 0.28 794 8.58 $8,225 $23,416,812 












 Cardiac rehabilitation (CR) is effective in reducing mortality and readmissions  
 Most patients are denied the benefits of CR due to low referral rates  
 In this economic analysis, CR was cost-effective with a mean ICER of $6096/QALY 
 Patients in CR programs experience greater health benefits over a lifetime  
 60% uptake of CR will lower readmissions by 823 events and 536 deaths over 10 
years 
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